Exelixis, Inc. (EXEL): Among Renaissance Technologies Portfolio’s Top Stock Picks
We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...
Renaissance Technologies Portfolio: Top 10 Stock Picks
The American quant hedge fund Renaissance Technologies is known for using statistical and mathematical tools to drive its ...
Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday?
Exelixis, Inc. (NASDAQ:EXEL) authorized repurchasing up to an additional $500 million of the company’s common stock before ...
Exelixis' (NASDAQ:EXEL) Earnings May Just Be The Starting Point
Exelixis, Inc. ( NASDAQ:EXEL ) recently posted some strong earnings, and the market responded positively. We did ...
Le Lézard2d
NTT DATA Launches Smart AI Agenttm to Accelerate Generative AI Adoption and Drive $2 Billion in Revenue by 2027
NTT DATA, a global digital business and IT services leader, today announced the international launch of its next-generation Smart AI Agenttm. This advanced AI tool is a cornerstone of the company's ...
Exelixis Announces a Newly Authorized $500 Million Stock Repurchase Program
Exelixis, Inc. (Nasdaq: EXEL) today announced that the company’s Board of Directors has authorized the repurchase of up to an additional $500 million of the company’s common stock before December 31, ...
Medscape3d
Diet Changes Show Promise in Early Prostate Cancer
A high omega-3, low omega-6 diet with fish oil led to a significant reduction in a biomarker for prostate cancer progression ...
BioSpace4d
Exelixis Looks to Next-Gen Cancer Drug as Cabometyx Underwhelms Again
Exelixis’ next-generation tyrosine kinase inhibitor zanzalintinib is being tested for colorectal cancer, renal cell carcinoma ...
Gastric Neuroendocrine Tumors Market Expected To Experience Major Growth By 2032, According To Delveinsight
Gastric Neuroendocrine Tumors market Forecast. DelveInsight's Gastric Neuroendocrine Tumors Market report offers an in-depth understanding of the epidemiol ...